Search - tctmd.com

Displaying 221 - 234 of 234

Sort: Relevancy | Date

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

TCTMD’s Top 10 Most Popular Stories for December 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

January 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

August 25, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

News Daily News

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Michael O'Riordan

April 05, 2018

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

January 28, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.